VEGF In Systemic Circulation Of ROP-infants

Withdrawn

• Conditions: Retinopathy of Prematurity (ROP)

• Registration Number: NCT01470430
• Lead Sponsor: University Hospital Freiburg

Brief Summary

The purpose of this study is to measure systemic levels of vascular endothelial growth factor (VEGF) and other proteins (e.g. IGF-1) in the systemic circulation of infants with retinopathy of prematurity (ROP) following ocular treatment with either intravitreal injections of anti-VEGF agents or retinal laser photocoagulation. The primary aim is to determine if serum VEGF levels change after treatment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-11-09
• Study First Submitted QC: 2011-11-09
• Study First Posted: 2011-11-11
• Study Start: 2012-03
• Status Verified: 2014-01
• Last Update Submitted: 2014-01-26
• Last Update Posted: 2014-01-28
• Primary Completion: 2014-03

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Clinical diagnosis of retinopathy of prematurity requiring treatment

Exclusion Criteria

• Anemia

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Systemic VEGF levels following treatment	16 weeks	comparing VEGF levels in serum of ROP infants treated with intravitreal anti-VEGF agents vs. retinal laser photocoagulation over 16 weeks post treatment

Secondary Outcome Measures

Name	Time	Method
Systemic levels of other growth factors (e.g. IGF-1)	16 weeks	comparing systemic levels of other (non-VEGF) factors in serum of ROP infants treated with intravitreal anti-VEGF agents vs. retinal laser photocoagulation

Trial Locations

Locations (1)

University Eye Hospital; 🇩🇪 Freiburg, Baden-Wuerttemberg, Germany